Do you want getting paid to do virtually nothing? I assumed so.

A number of savvy buyers know that they will generate heaps of passive earnings with dividend-paying shares. These three companies are extra than simply dependable dividend payers; they’re identified for elevating their dividend payouts yr after yr. Here is how they might present ever-increasing dividend funds to your brokerage account.

Picture supply: Getty Photos.

1. Abbott Laboratories

This healthcare conglomerate’s COVID-19 assessments made it a inventory market darling in 2021. Shares of Abbott Laboratories (ABT 0.44%) have tumbled round 27% for the reason that starting of 2022 in response to subsiding demand for COVID assessments. Now the inventory presents a tempting 1.8% dividend yield that would rise considerably within the years forward.

Within the second quarter, COVID-19 testing-related gross sales fell to $2.Three billion from $3.Three billion through the first quarter of 2022. Fortunately for long-term buyers, the corporate may report important earnings progress even when COVID-19 gross sales fall off a cliff.

Declining COVID-19 testing income is not a serious situation for this diversified conglomerate as a result of its diabetes-care section is about to rocket larger. In Could, the FDA granted clearance to Abbott’s FreeStyle Libre Three system. This machine is barely the dimensions of a few pennies stacked collectively, however as soon as a affected person sticks it on her or his arm, it displays blood sugar ranges always for 2 weeks.

Fixed monitoring results in fewer interventions in costly hospitals, so insurers and authorities payers are desperate to reimburse sufferers for the units. With glucose monitoring gross sales about to explode larger, Abbott may approve some massive dividend raises within the foreseeable future.

2. CVS Well being

Shares of CVS Well being (CVS -0.66%) surged late final yr when the corporate introduced that it might start elevating its dividend payout once more. Since then, the inventory has been in a holding sample.

At current costs, shares of CVS Well being provide a 2.2% yield that would develop considerably within the years forward. Along with 1000’s of retail pharmacies, this conglomerate owns a pharmacy advantages administration enterprise that boasts greater than 110 million plan members.

Integrating a pharmacy advantages administration enterprise is one benefit its friends within the retail pharmacy house cannot match, and it is not the corporate’s solely massive benefit. CVS Well being beforehand paused elevating its dividend payout to repay its acquisition of Aetna, a well being insurer that at present collects premiums from an estimated 35 million members.

CVS Well being’s distinctive mixture of associated companies allowed the corporate to lift its dividend payout by 10% this yr. With none rivals combining a big retail footprint with a well being advantages administration enterprise, the most recent massive payout bump could possibly be the primary of many within the years forward.

3. AbbVie

AbbVie (ABBV -0.80%) was as soon as the pharmaceutical section of Abbott Laboratories. Shares of AbbVie provide an above-average yield of 4.2% that would climb even larger.

For the reason that drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the again of its lead drug, Humira. Second-quarter gross sales of Humira rose 9.6% yr over yr to a surprising $4.7 billion within the U.S. Sadly, worldwide Humira income fell 13.8% to $699 million.

AbbVie presents an above-average dividend now as a result of U.S. Humira gross sales will quickly go the identical means as worldwide gross sales. An interchangeable biosimilar model of the anti-inflammatory blockbuster grew to become out there within the U.S. this July.

AbbVie buyers can anticipate their dividend payouts to proceed rising within the face of Humira competitors as a result of the corporate has new blockbuster medication to choose up the slack. Second-quarter gross sales of Rinvoq, a brand new arthritis drug, and Skyrizi, a brand new psoriasis drug, soared 75% yr over yr to a mixed $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders may see extra massive payout bumps within the years forward.